Gasthuiszusters Antwerpen
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology department at Gasthuiszusters Antwerpen is conducting research focused on atrial fibrillation and the prevention of stroke or systemic embolism. Current studies aim to evaluate a new oral anticoagulant compared with established therapy, assessing both efficacy in reducing clot‑related events and overall bleeding risk.
- Evaluation of innovative anticoagulant strategies for stroke prevention
- Comparative safety analysis with standard treatment options
- Optimization of risk‑benefit balance in patients at high thrombotic risk
These trials seek to improve outcomes for individuals with irregular heart rhythms by offering potentially safer and more effective prevention methods, reinforcing the site’s commitment to advancing cardiovascular care.
Neoplasms
In the oncology‑focused arm of the cardiology department, investigators are studying the continued use and safety profile of darolutamide in patients with advanced prostate cancer. The research evaluates long‑term tolerability and aims to confirm that ongoing treatment remains beneficial without unexpected adverse effects.
- Long‑term safety monitoring of targeted cancer therapy
- Assessment of treatment continuation outcomes in prostate malignancy
- Identification of any emerging safety signals during extended use
By focusing on both efficacy and patient safety, the site contributes valuable data that may shape future standards for managing neoplastic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 283 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 276 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 42 by active trials.
- 1AstraZeneca AB5active
lock +41 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International15trials
lock +35 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gasthuiszusters Antwerpen
lock Showing 1 of 179 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 283 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2018-09-11 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.